NMD670

Phase 2Small molecule

NNMD Pharma A/S

NMD670 is one of 36 small molecule programs targeting Myasthenia Gravis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myasthenia GravisRecruiting

Spinal Muscular AtrophyRecruiting

Myasthenia GravisPhase 2

Recruiting

Spinal Muscular AtrophyPhase 2

Recruiting

Competition

Competitive Landscape

27 competitors in Myasthenia Gravis

#DrugCompanyPhaseTrials

Ultomiris

AstraZeneca

Approved

4 2

Vyvgart

Argenx

Approved

13 3

Rysodeg

UCB

Approved

2 4

Rituxan

Roche

Phase 3

7 5

Rayos

RRoxane Laboratories

Approved

—6

Proair HFA

GGlaxo Dba Glaxosmithkline

Fabhalta

3 8

Blincyto

Amgen

Phase 3

2 9

Actemra

CCelltrion

Phase 3

2 10

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Myasthenia Gravis

NCT06414954

Clinical

Trials by Indication[1]

Spinal Muscular Atrophy1 trial

Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy

Recruiting·NNMD Pharma A/S·Phase 2·NCT05794139·54 enrolled

Charcot-Marie-Tooth disease1 trial

Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease

Completed·NNMD Pharma A/S·Phase 2·NCT06482437·81 enrolled

Myasthenia Gravis1 trial

A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 3 Dose Levels of NMD670 Over 21 Days in Adult Patients With AChR/MuSK-Ab+ Myasthenia Gravis

Recruiting·NNMD Pharma A/S·Phase 2·NCT06414954·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for NMD670. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NMD670 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NMD670. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NMD Pharma A/S company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNMD Pharma A/S

NMD670

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Spinal Muscular Atrophy1 trial

Charcot-Marie-Tooth disease1 trial

Myasthenia Gravis1 trial

References

Drug Info

Quick Facts

Related News